Strategy Asset Managers’s GSK GSK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q1 | – | Sell |
-24,866
| Closed | -$1.14M | – | 263 |
|
|
2020
Q4 | $1.14M | Sell |
24,866
-1,850
| -7% | -$85K | 0.27% | 71 |
|
|
2020
Q3 | $1.26M | Buy |
26,716
+412
| +2% | +$20.6K | 0.33% | 58 |
|
|
2020
Q2 | $1.34M | Buy |
26,304
+362
| +1% | +$18.6K | 0.36% | 53 |
|
|
2020
Q1 | $1.23M | Sell |
25,942
-1,776
| -6% | -$94.7K | 0.4% | 52 |
|
|
2019
Q4 | $1.63M | Buy |
27,718
+884
| +3% | +$49.2K | 0.4% | 46 |
|
|
2019
Q3 | $1.43M | Sell |
26,834
-1,198
| -4% | -$61.6K | 0.43% | 38 |
|
|
2019
Q2 | $1.4M | Sell |
28,032
-650
| -2% | -$32.6K | 0.4% | 43 |
|
|
2019
Q1 | $1.5M | Buy |
28,682
+64
| +0.2% | +$3.2K | 0.34% | 85 |
|
|
2018
Q4 | $1.37M | Sell |
28,618
-1,680
| -6% | -$82.7K | 0.33% | 70 |
|
|
2018
Q3 | $1.52M | Sell |
30,298
-216
| -0.7% | -$11K | 0.31% | 90 |
|
|
2018
Q2 | $1.54M | Buy |
30,514
+442
| +1% | +$22.3K | 0.33% | 86 |
|
|
2018
Q1 | $1.47M | Sell |
30,072
-177
| -0.6% | -$8.24K | 0.32% | 84 |
|
|
2017
Q4 | $1.34M | Sell |
30,249
-3,158
| -9% | -$146K | 0.26% | 90 |
|
|
2017
Q3 | $1.7M | Buy |
33,407
+848
| +3% | +$43K | 0.35% | 84 |
|
|
2017
Q2 | $1.75M | Buy |
32,559
+14,762
| +83% | +$787K | 0.36% | 86 |
|
|
2017
Q1 | $938K | Buy |
17,797
+845
| +5% | +$42.9K | 0.2% | 86 |
|
|
2016
Q4 | $826K | Sell |
16,952
-358
| -2% | -$17.7K | 0.18% | 87 |
|
|
2016
Q3 | $933K | Buy |
17,310
+1,608
| +10% | +$88.2K | 0.21% | 90 |
|
|
2016
Q2 | $851K | Buy |
15,702
+716
| +5% | +$37.7K | 0.19% | 95 |
|
|
2016
Q1 | $760K | Buy |
14,986
+1,648
| +12% | +$82.1K | 0.17% | 98 |
|
|
2015
Q4 | $673K | Buy |
13,338
+486
| +4% | +$24.8K | 0.15% | 93 |
|
|
2015
Q3 | $618K | Buy |
12,852
+330
| +3% | +$17.2K | 0.15% | 95 |
|
|
2015
Q2 | $652K | Buy |
12,522
+1,180
| +10% | +$66.4K | 0.15% | 93 |
|
|
2015
Q1 | $654K | Buy |
11,342
+1,484
| +15% | +$85.1K | 0.14% | 92 |
|
|
2014
Q4 | $527K | Buy |
9,858
+1,027
| +12% | +$57.5K | 0.11% | 95 |
|
|
2014
Q3 | $507K | Buy |
8,831
+902
| +11% | +$55.3K | 0.11% | 93 |
|
|
2014
Q2 | $530K | Buy |
7,929
+164
| +2% | +$11.1K | 0.11% | 86 |
|
|
2014
Q1 | $519K | Buy |
7,765
+870
| +13% | +$58.8K | 0.11% | 89 |
|
|
2013
Q4 | $460K | Buy |
6,895
+1,170
| +20% | +$75.9K | 0.1% | 93 |
|
|
2013
Q3 | $359K | Buy |
5,725
+1,001
| +21% | +$64.4K | 0.08% | 100 |
|
|
2013
Q2 | $295K | Buy |
+4,724
| New | +$300K | 0.07% | 115 |
|
Other funds holding GSK
BCIM
Strategy Asset Managers's GSK Position: Q1 2021 in Review
Strategy Asset Managers sold out of GSK (GSK) in Q1 2021, closing a stake of 24,866 shares — an estimated $1.14M sold.
Strategy Asset Managers first reported a position in GSK in Q2 2013 and held it in 31 quarters. The position peaked at $1.75M in Q2 2017. 774 funds tracked by Wall St. Rank hold GSK as of Q1 2021.
- Strategy Asset Managers reported no remaining GSK position as of Q1 2021 after selling out during the quarter.
- Strategy Asset Managers sold 24,866 GSK shares in Q1 2021, an estimated $1.14M.
- Strategy Asset Managers first reported a position in GSK in Q2 2013 and held it in 31 quarters.
- Strategy Asset Managers's GSK position peaked at $1.75M in Q2 2017.
- 774 funds tracked by Wall St. Rank held GSK as of Q1 2021.
Based on Strategy Asset Managers's 13F filing for Q1 2021, filed 12 May 2021.